Tech Company Financing Transactions
Bicara Therapeutics Funding Round
On 12/12/2023, Bicara Therapeutics secured $165 million in Series C funding from Braidwell, The Rise Fund and TPG Capital.
Transaction Overview
Company Name
Announced On
12/12/2023
Transaction Type
Venture Equity
Amount
$165,000,000
Round
Series C
Investors
Proceeds Purpose
The new funds will be used primarily for the clinical development of lead asset BCA101, which is designed to be both a monotherapy and combo treatment with Keytruda for patients with solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 Main St
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Claire Mazumdar
Chief Financial Officer
Ivan Hyep
Chief Operating Officer
Ryan Cohlhepp
Browse more venture capital transactions:
Prev: 12/12/2023: NeoCarbon venture capital transaction
Next: 12/12/2023: Durable venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs